Prostate News and Research

RSS

AUA Foundation joins AUA in response to the ACS updated prostate cancer screening guidelines

The American Urological Association Foundation joins the AUA in its response to the American Cancer Society updated prostate cancer screening guidelines highlighting the importance of shared decision-making between patients and physicians.

3 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Robotic surgical technology with its three-dimensional, high-definition view gives surgeons the sensation of touch, even as they operate from a remote console. A new study describes the phenomenon, called intersensory integration, and reports that surgical outcomes for prostate cancer surgery using minimally invasive robotic technology compare favorably with traditional invasive surgery.

3 Mar 2010

Lotus Pharmaceuticals adds five new prescription drugs to its products

Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that it had added five new prescription drugs to its products delivered through its national sales channels.

3 Mar 2010

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.

3 Mar 2010

Study shows cryoablation technique offers a potential treatment for breast cancer

Freezing a cancer kills it in its place, and also appears to generate an immune response that helps stop the cancer's spread, leading to improved survival rates over surgery, according to a new study in mice from researchers at the University of Michigan Comprehensive Cancer Center.

3 Mar 2010

Generic version of Flomax Capsules receives FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate gland causes problems with urination.

2 Mar 2010

Scientists show omega-3 fatty acid and its derivatives kill neuroblastoma cancer cells

The next treatment for cancer might come from fish says a new research report published in the March 2010 print edition of the FASEB Journal (http://www.fasebj.org). In the report, scientists show that the omega-3 fatty acid, "docosahexaenoic acid" or "DHA," and its derivatives in the body kill neuroblastoma cancer cells.

2 Mar 2010

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

AdMeTech Foundation announced today that its President and CEO Dr. Faina Shtern will testify on March 4 before the U.S. House Committee on Oversight and Government Reform on how health care reform highlights the need for increased funding for research aimed at creating accurate, life-saving diagnostic tools for prostate cancer, which will improve screening, prevention, early detection and reduce health costs.

2 Mar 2010

RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for treatment of CRPC are lacking and healthcare professionals must consider several factors, including serum markers, patient age and pre-existing comorbidities when choosing between second-line hormonal therapy and chemotherapy for treatment of CRPC.

2 Mar 2010

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

OncoGenex Pharmaceuticals, Inc., announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as custirsen (OGX-011) that is designed to knock down treatment resistance in the cells and enhance the effectiveness of cancer therapies.

1 Mar 2010

ProUroScan prostate imaging system 510(k) application: Inclement weather delays FDA processing

ProUroCare Medical, Inc., a provider of proprietary medical imaging products, indicates that the Food and Drug Administration has informed the industry that the processing of 510(k) applications, which includes the ProUroScan™ prostate imaging system, has been delayed because of the inclement weather in February that impacted the Washington, D.C. area.

26 Feb 2010

New Robotic Surgical Simulator created for robot-assisted surgery

A collaboration between the Center for Robotic Surgery at Roswell Park Cancer Institute and the University at Buffalo's School of Engineering and Applied Sciences has produced one of the world's first simulators that closely approximates the "touch and feel" of the da Vinci- robotic surgical system.

26 Feb 2010

New dietary supplement blocks triggering mechanism causing breast cell mutations

Every 13 minutes a woman loses her battle with breast cancer and in 2009 alone more than 27,000 men died from prostate cancer. These powerful statistics continue to fuel research and new developments. With tens of millions of dollars in financial support from the National Cancer Institute and the U.S. Department of Defense, scientists have identified when estrogen metabolism is out of balance it can start the process leading to breast cell mutations.

26 Feb 2010

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Manhattan Scientifics Inc., a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC.

26 Feb 2010

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers - the most common cancer in Australian men.

25 Feb 2010

Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC

Kinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC) who have not had prior chemotherapy.

25 Feb 2010

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13󈝾 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.

25 Feb 2010

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.

25 Feb 2010

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

US HIFU, a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device, has announced its intention to fund a landmark multi-center trial to study focal therapy for localized prostate cancer. Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH), along with Hashim Uddin Ahmed, MRC clinical research fellow, will lead the trial.

25 Feb 2010

Prostate News and Research

AUA Foundation joins AUA in response to the ACS updated prostate cancer screening guidelines

Allergan celebrates 20th anniversary of BOTOX in Canada

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Lotus Pharmaceuticals adds five new prescription drugs to its products

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Study shows cryoablation technique offers a potential treatment for breast cancer

Generic version of Flomax Capsules receives FDA approval

Scientists show omega-3 fatty acid and its derivatives kill neuroblastoma cancer cells

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

ProUroScan prostate imaging system 510(k) application: Inclement weather delays FDA processing

New Robotic Surgical Simulator created for robot-assisted surgery

New dietary supplement blocks triggering mechanism causing breast cell mutations

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News